First insight into the drug resistance pattern of Mycobacterium tuberculosis in Dohuk, Iraq: Using spoligotyping and MIRU-VNTR to characterize multidrug resistant strains  by Merza, Muayad A. et al.
Journal of Infection and Public Health (2011) 4, 41—47
First insight into the drug resistance pattern of
Mycobacterium tuberculosis in Dohuk, Iraq: Using
spoligotyping and MIRU-VNTR to characterize
multidrug resistant strains
Muayad A. Merzaa,b,∗, Parissa Farniaa, Ahmad M. Salihb,
Mohammad Reza Masjedia, Ali Akbar Velayati a
a Mycobacteriology Research Center (MRC), National Research Institute of Tuberculosis and Lung
Diseases (NRITLD), Shahid Beheshti University (Medical Campus), Darabad, Tehran, Iran
b Azadi Teaching Hospital, College of Medicine University of Dohuk, Dohuk, Kurdistan, Iraq
Received 27 August 2010; received in revised form 9 November 2010; accepted 16 November 2010
KEYWORDS
Tuberculosis;
Multidrug resistant;
Iraq;
Drug susceptibility
testing;
Molecular genotyping
Summary The objectives of this study were to determine drug resistance pat-
tern in new and previously treated tuberculosis (TB) patients, to assess function
of TB control program, and to characterize multidrug resistant TB (MDR-TB) by
molecular ﬁngerprinting methods. Anti-micorbial susceptibility testing (AST) to the
ﬁrst line anti-TB drugs was performed on Löwenstein—Jensen (middlebrook 7H10)
medium according to the proportion method. Molecular ﬁngerprinting of all MDR
strains was performed by spoligotyping and MIRU-VNTR. Mycobacterium tubercu-
losis strains were isolated from 53 Iraqi patients with pulmonary TB. Thirty eight
patients (71.7%) tested cases, and 15 (28.3%) were previously treated. Four of the
38 new cases (10.5%) had resistant, of which 3 (7.9%) were MDR. Eight (53.3%) of the
15 previously treated patients had resistant strains, of which 7 (46.7%) were MDR.
Spoligotyping of MDR strains showed CAS family (40%) as the predominant genotype.
Using MIRU-VNTR typing, all isolates had a unique proﬁle. MDR-TB prevalence is
higher among previously treated patients than among the new cases. The many drug
resistant strains, in absence of evidence of recent transmission and in combination
with the many previously treated cases, highlight the need for an improved con-
trol program, coupled with a need to improve detection rate and early diagnosis of
MDR-TB.
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Ltd. All rights reserved.
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Introduction
Despite the adoption of Directly Observed Ther-
apy Short-Course (DOTS) strategy by World Health
Organization (WHO), TB prevalence continues to
increase worldwide, particularly in developing
countries. This has been attributed to the human
immunodeﬁciency virus (HIV) pandemic and emer-
gence of drug resistant strains [1]. Additional
reasons for the increase are related to poverty,
migration, ethnic conﬂicts and abuse of narcotic
substances. Of great importance are also inad-
equate health care generally attributed to poor
performance of NTPS. These factors may lead to
the development of drug resistance, which how-
ever, can be counteracted by proper health control
measures [2]. The emergence of MDR-TB, that is
Mycobacterium tuberculosis strains resistant to at
least isoniazid (INH), rifampicin (RMP), poses a sig-
niﬁcant global and public health concern. Such
cases are difﬁcult to cure, requiring the use of sec-
ond line drugs that are more toxic and expensive
than the ﬁrst line regimen [3]. The recently pub-
lished WHO report on Global TB Control in 2009
stated that there were an estimated 0.5 million
cases of MDR-TB in 2007 [1]. Recently, M. tubercu-
losis strains that are extensively drug resistant-TB
(XDR-TB), i.e. MDR-TB strains resistant to at least
three of the six classes of second-line drugs
(aminoglycosides, polypeptides, ﬂuoroquinolones,
thioamides, cycloserine, and para-aminosalicylic
acid) have been described [4,5]. According to a
2000—2004 survey of International TB Laboratories
conducted by the WHO and US Centers for Dis-
ease Control (CDC), 20% of M. tuberculosis isolates
were MDR-TB and 2% were XDR-TB [6]. Anti-TB drug
resistance is present everywhere in the world and
MDR-TB is considered to be widespread today. A
high prevalence of MDR-TB cases has been noticed
in China, India, and the Russian Federation. China
and India carry approximately 50% of the global
burden and the Russian Federation a further 7%
[7].
Iraq is one of the countries in WHO Eastern
Mediterranean Region (WHO-EMR) with a rela-
tively high TB incidence rate (56/100,000) and
low case detection rate (45%) [1]. This may be
attributed to the unstable situation in society, low
socio-economic status, and unsatisfactory treat-
ment. The DOTS strategy has been adopted in
Iraq since 1998, except for the three northern
Iraq provinces (Dohuk, Erbil and Sulaimani), which
implemented DOTS since 2001. In northern Iraq, the
management of TB patients is based primarily on
smear microscopic examination as there is no cul-
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ure and antimicrobial susceptibility testing (AST)
8]. In case of treatment failure or suspicion of
rug resistance, patients are referred to Baghdad
r neighbouring countries for further investiga-
ions. The DNA ﬁngerprinting methods have been
idely used to characterize drug resistance strains,
articularly MDR-TB, in order to better under-
tand the origin and propogation of drug resistant
trains in a speciﬁc location. The ﬁrst effec-
ive strains genotyping technique, RFLP-IS6110,
as gained recognition as the international stan-
ard for epidemiological typing of M. Tuberculosis
9]. Recently, spoligotyping, a highly polymor-
hic direct repeat (DR) locus in the MTB genome
as been used to provide epidemiological infor-
ation of strain relatedness [10]. More recently,
ycobacterial interspersed repetitive unit-variable
umber of tandem repeats (MIRU-VNTR) analysis
ave been established to track epidemic strains
11].
Because the TB drug resistance patterns and
enotype characterization of resistant strains are
urrently unknown in Dohuk, the goal of the
resents study was to determine drug resistance
attern in new and previously treated TB patients,
o evaluate TB control programs, to determine risk
actors associated with MDR-TB and ﬁnally to char-
cterize MDR strains by molecular ﬁngerprinting
ethods.
aterials and methods
pecimen collection
ll smear positive pulmonary specimens were col-
ected between June 2008 and June 2009 at the
TP center of Dohuk province — Iraq. Sampling
as deemed to be representative at the province
evel, as all TB cases had attended directly or
ad been referred from other health centers to
he Dohuk NTP. Classical epidemiology data were
ollected by using standard questionnaires. Infor-
ation was obtained on sex, age, country of birth,
ecent smear positivity, previous history of TB, and
resent address. The specimens were shipped to
ycobacteriology Research Center (MRC), National
esearch Institute of Tuberculosis and Lung Dis-
ases (NRITLD), Tehran, Iran for culturing and
ST.solation of M. tuberculosis
he pulmonary specimens were processed for
ulture by digestion, decontamination and concen-
D osis
t
w
s
t
M
i
r
[
A
A
(
C
f
b
s
T
w
m
w
2
m
w
f
D
D
s
K
1
d
D
A
o
d
l
w
r
a
r
h
m
t
c
l
t
c
a
p
p
S
T
i
s
p
w
w
o
i
a
b
s
l
t
i
l
R
C
I
b
O
e
o
3
c
T
p
a
a
w
i
A
T
a
i
w
a
T
1
(
t
E
M
(rug resistance pattern of Mycobacterium tubercul
ration following modiﬁed Petroff’s method and
ere inoculated into 2 tubes of LJ media. The
lants were examined for growth once weekly up
o 8 weeks [12]. The isolates were identiﬁed as
. tuberculosis by using biochemical tests, includ-
ng production of niacin, catalase activity, nitrate
eduction, pigment production and growth rate
12].
ST
STs were performed for INH, RMP, streptomycin
STM), ethambutol (EMB), and pyrazinamide (PZA).
olonies from the surface of LJ medium were trans-
erred into sterile test tubes containing 6—8 glass
eads and 3.0mL of Middlebrook 7H9 broth. The
uspension was adjusted to 1 McFarland standard.
hereafter, dilutions of 1/10, 1/1000 and 1/100,000
ere prepared and inoculated into drug-containing
iddlebrook and controls. The drug concentrations
ere as follows: 0.2g/mL INH, 40g/mL RMP,
g/mL EMB and 4g/mL STM by the proportion
ethod [13]. Susceptibility to pyrazinamide (PZA)
as tested using a two-phase medium and two dif-
erent concentration of inocula.
NA ﬁngerprinting
NA of each MDR-TB isolate was extracted and
poligotyping was performed as described by
amerbeek et al. [10]. For MIRU-VNTR genotyping,
2 loci of the MDR strains were ampliﬁed by PCR as
escribed previously [11,14].
eﬁnitions
ny drug resistance was deﬁned as resistance to
ne or more ﬁrst-line drugs. Monoresistance was
eﬁned as resistance to only one of the ﬁve ﬁrst-
ine drugs (INH, RMP, STM, EMB, and PZA). MDR-TB
as deﬁned as M. tuberculosis strains that were
esistant to at least INH and RMP. Drug resistance
mong new cases was deﬁned as the presence of
esistant isolates of M. tuberculosis in patients who
ad not been exposed to anti-TB treatment for as
uch as 1 month; previously called primary resis-
ance. Drug resistance among previously treated
ases was deﬁned as the presence of resistant iso-
ates of M. tuberculosis in patients who had been
reated for TB for 1 month or more; previously
alled acquired resistance [7]. A cluster was deﬁned
s two or more isolates obtained from different
atients having identical spoligotype or MIRU-VNTR
attern [15].
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tatistical analysis
he AST results obtained were analyzed by enter-
ng the data in a binary format as Microsoft Excel
preadsheet. Frequencies and variables were com-
ared by Chi-square test or Fisher’s exact test
henever necessary. A P-value of less than 0.05
as considered statistically signiﬁcant. The spolig-
typing results were compared with those in the
nternational SpolDB4 database [16] and further
nalyzed with ‘Spotclust’, using a mixture model
uilt on the SpolDB3 database [17]. Thereafter, the
poligotypes were assigned to families and subfami-
ies. The rate of diversity was calculated by dividing
he number of spoligotypes by the total number of
solates found. The MIRU-VNTR results were ana-
yzed by using the MIRU-VNTRPlus database [18].
esults
haracteristics of patients
n total, 86 smear positive pulmonary specimens
etween June 2008 and June 2009 were included.
ut of 86 patients, 30 specimens (34.9%) were
xcluded because they were either culture negative
r had culture contamination. In addition another
specimens (3.5%) were excluded because their
ultures were mycobacteria other than TB (MOTT).
he study therefore consisted of 53 culture positive
atients. Of the 53 patients, 38 were new TB cases
nd 15 were previously treated patients. The mean
ge of the patients was 49.10 yr (±2.15). There
ere 37 males (69.8%) and 16 females (30.2%), giv-
ng a sex ratio of 2.3:1.
ST of M. Tuberculosis
able 1 demonstrates patterns of drug resistance
mong the strains. Of the M. tuberculosis strains
solated from each of 54 smear positive, 41 (77.4%)
ere susceptible to all ﬁrst line drugs investigated,
nd 12 (22.6%) were resistant to at least one drug.
hirty eight patients (71.7%) were new cases, and
5 (28.3%) were previously treated. Ten patients
18.7%) had MDR-TB, with the most common pat-
ern of resistance to the three drugs INH, RMP and
MB (4, 7.4%) shown in Table 1.
There were certain variables associated with
DR-TB cases. Among the 10 MDR-TB patients, 7
70%) had been previously treated while among the
8 patients with non-MDR-TB only 8 patients (16.7%
-value = 0.003) had been previously treated. MDR-
B was found in patients with mean age 51.3 (±3.3)
nd was higher in males (8, 80%).
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Table 1 Resistance to ﬁrst-line drugs among M. tuberculosis strains.
Type New cases Previously treated cases Total P-value
Total strains
Investigated 38 15 53
All susceptible 34 (89.5%) 7 (46.7%) 41 (77.4%) <0.001
Any drug resistance 4 (10.5%) 8 (53.3%) 12 (22.6%) 0.013
INH 4 (10.5%) 8 (53.3%) 12 (22.6%)
RMP 3 (7.9%) 7 (46.7%) 10 (18.9%)
PZA 0 2 (13.3%) 2 (3.8%)
EMB 1 (2.6%) 6 (40.0%) 7 (13.2%)
STM 0 2 (13.3%) 2 (3.8%)
Monoresistance 1 (2.6%) 1 (6.7%) 2 (3.8%) 0.97
INH 1 (2.6%) 1 (6.7%) 2 (3.8%)
RMP 0 0 0
PZA 0 0 0
EMB 0 0 0
STM 0 0 0
Multidrug resistance 3 (7.9%) 7 (46.7%) 10 (18.7%) 0.006
INH +RMP 2 (5.3%) 1 (6.7%) 3 (5.6%)
INH +RMP+PZA + EMB 0 1 (6.7%) 1 (1.9%)
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Genotypes and transmission analysis of
MDR-TB cases
To gain insight into the genotypes and transmission
patterns of MDR strains, the isolates were subjected
to spoligotyping and MIRU-VNTR, respectively. The
10 analyzed MDR strains yielded 9 different spoligo-
patterns resulting in an overall diversity of 0.90.
Based on the spoligotype patterns, there was
only one cluster consisting of two patients. The
remaining drug resistant TB patients had isolates
with unique spoligotype patterns (Fig. 1). Family
assignment by use of the SpolDB4 database and
‘Spotclust’ identiﬁed the CAS family as the pre-
dominant genotype (n = 4, 40.0%), followed by T1,
Haarlem3 and Family33 each (n = 2, 20%). Using
MIRU-VNTR typing, all isolates had a unique proﬁle,
and all of them showed differences in at least one
locus (Fig. 1). The 2 CAS strains of the only spolig-
otyped cluster exhibited identical spoligopatterns,
but they had MIRU-VNTR patterns that differed by
two repeats at MIRU10, two repeats at MIRU23 and
three repeats at MIRU26. The two patients in this
cluster were relatives lived in same district and had
been diagnosed and treated in the same Dohuk NTP.Discussion
Although the social situation is unstable and inse-
cure in Iraq, the TB control services continue to be
s
t
O
r(6.7%) 1 (1.9%)
(20.0%) 4 (7.4%)
(6.7%) 1 (1.9%)
rovided according to DOTS program whenever and
herever possible [1]. The WHO assumed that the
ncidence rate of TB in Iraq is stable (56/100,000),
ut there is no reliable data from which to assess
ncidence trends [1]. Iraq has a higher incidence of
B than the majority of neighbouring countries [1],
ut knowledge of resistance patterns and trends has
ot yet been studied. Such information is essen-
ial in order to ascertain appropriate treatment
trategies. To our knowledge, the present analy-
es is the ﬁrst prospective study about anti-TB drug
esistance pattern and molecular epidemiology of
DR-TB strains in Iraq.
In this study, we found that the rate of any drug
esistance and MDR-TB was (22.6%) and (n = 12 and
0 respectively) (18.7%), respectively. The rate is
igher compared to ﬁgures from Turkey [19], and
atar [20], whereas the rate is lower than those
eported from Iran [21]. In the present study, the
ost common drug resistance pattern INH resis-
ance (12, 22.6%), followed by RMP resistance (10,
8.9%). In a study from Riyadh, the same resistance
attern was reported [22]. However, other resis-
ance patterns have also been reported. In some
tudies [19,20], resistance to INH and STM was
ore frequently reported, whereas in a 15 yearsurveillance study in Saudi Arabia [23], resistance
o INH and EMB was the most common pattern.
ne possible explanation of our relatively high
ate of RMP resistance is attributed to its use in
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MIRU-VNTR 
profile 
Spoligopatterns no (%) 
Spoligotyping  
Octal number 
Phylogene
tic clade 
  4 (40)  CAS 
236426153433  1 (10) 703727740003771 CAS 
234426153433 
 2 (20)) 503727740003771 CAS 
236424183433 
232424143322  1 (10) 503767400005771 CAS 
  2 (20)  T 
234326143323  1 (10) 747727777740771 T1 
232124142323  1 (10) 747767777740771 T1 
  2 (20)  Haarlem 
235424143323  1 (10) 547727737700771 Haarlem3 
235324143323  1 (10) 547727437600771 Haarlem3 
  2 (20)  F33 
233226142322  1 (10) 547737777603771 F33 
233426123223  1 (10) 555767437610771 F33 
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he treatment of non-speciﬁc infections as well
s for certain infectious diseases like brucellosis.
TM resistance (2, 3.8%) was less common in this
tudy since the widely used EMB as a fourth drug in
he WHO standard regimen for new cases, and the
se of STM occurs only during the ﬁrst 2 months
n the WHO standard retreatment regimen. Fur-
her, we found that all RMP resistant strains also
ere resistant to INH. This is a common condi-
ion and has e.g. been reported by Al-Orainey
t al. who found that majority of isolates from
atients with acquired resistance to RMP were also
esistant to INH [22]. It is well known that monore-
istance to RMP is rare, whereas monoresistance
o INH is common [24]. Thus, we propose to apply
h
c
f
oing and MIRU-VNTR) of MDR-TB cases.
his fact in our TB laboratories, since there are
imited resources for detecting MDR-TB strains in
raq.
In the present study, the rate of MDR-TB in new
nd previously treated cases was 3 (7.9%) and 7
46.7%), respectively. Similarly, a high prevalence
ate of MDR-TB was seen in Iran, whereas lower
ate was reported from other countries in the
egion [19,20]. Overall, lower MDR-TB rates, 2% for
ew cases and 29.4% for previously treated cases,
ere reported from WHO-EMR in 2004 [25]. The
igh rates of resistance among previously treated
ases are serious problems, and may indicate inef-
ective DOTS implementation in Iraq. Although
ur treatment success rate (86%) is in line with
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the WHO’s target (85%), the 45% case detection
rate is under the WHO target (70%) [1], which is
another indicator of poor TB control performance.
Dye and Williams stated that case detection and
cure rates are two variables that act synergisti-
cally [26]. When either is low, the other cannot
succeed alone resulting in emergence of drug resis-
tance.
With respect to risk factors of MDR-TB, we doc-
umented that a was signiﬁcantly (P-value = 0.003)
associated with MDR-TB, which has also been docu-
mented in other publications [27,28]. Further, we
demonstrated that patients with mean age 51.3
yr (±3.3), and male sex were associated risk fac-
tors for infection by MDR-TB, but these ﬁndings
were not statistically signiﬁcant. The explanation
for increase risk of MDR-TB in this age group may be
attributed to recent decreases in circulating drug-
resistant strains or it could reﬂect the year in which
effective anti-TB drugs such as RMP were intro-
duced. In a review by Faustini et al. it was found
that MDR-TB was more common in patients under
65 years, but the association was weak and more
heterogeneous in patients under 45 [29]. They also
stated that MDR-TB incidence was not affected by
gender. It has otherwise been hypothesized that
women are more compliant with treatment and
therefore less likely to receive inadequate treat-
ment [29].
In this study, molecular genotyping of MDR iso-
lates found the CAS family to be the predominant
genotype (n = 4, 40.0%). In contrast to our ﬁnding,
global MDR-TB outbreaks have been associated with
Beijing and Haarlem families [30]. The CAS fam-
ily is essentially localized in Central and Middle
Eastern Asia [16]. It belongs to ancient TB and its
prevalence is steadily decreasing from South Asia to
Western Asia [31]. This genotype might be an ances-
tor of the Beijing lineage since it clusters close to
Beijing when analyzed by a combination of MIRU-
VNTR and spoligotyping [32]. Among the 10 MDR-TB
patients with ﬁngerprinting information, 2 were
part of a single cluster with a similar spoligopat-
tern (CAS family), but with different MIRU-VNTR
proﬁle (234426153433 and 236424183433) (Fig. 1).
Based on this ﬁnding, further studies with larger
sample size are warranted to understand molecular
epidemiology of MDR strains in this geographi-
cal location. Assuming that clustering represents
recent transmission, the low clustering rate of MDR
strains in this study suggests that recent transmis-
sion in Dohuk plays a lesser role in the occurrence
of MDR-TB, and the most MDR strains in Dohuk are
due to ﬂawed patient management; effective TB
control measures have not yet been achieved in
Iraq.M.A. Merza et al.
The small sample size is the main limitation to
his study. Another limitation is that no strains from
mear negative pulmonary TB, extra-pulmonary TB,
nd TB cases from private sector were included,
lthough the study included almost all smear pos-
tive specimens for 1 year at a governmental NTP
enter in Dohuk province.
In conclusion, the rate of drug-resistance in pul-
onary TB cases, especially MDR-TB, was higher
mong previously treated patients than among
he new cases. This is likewise the consequence
f repeated treatments. The many drug resistant
trains in absence of evidence of recent trans-
ission in combination with the many previously
reated cases highlight the need for an improved
ontrol program. This must be coupled with improv-
ng case detection rate and early diagnosis of
DR-TB. This is especially important for high-risk
atients, in order to reduce the spread and devel-
pment of resistance.
Further prospective studies encompassing all
TPs in Iraq are warranted with the implementation
f AST and molecular analysis of drug resistance
trains, to better understand the prevalence, pat-
ern and transmission trends of drug resistance.
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